Gilead Sciences, Inc. (GILD): Piling on the Phase 3 Data

Page 1 of 2

Gilead Sciences, Inc. (NASDAQ:GILD) is piling on the phase 3 data for its hepatitis C drug sofosbuvir, announcing two more successful trials for the drug formerly known as GS-7977.

At this point, it looks extremely likely that sofosbuvir will be approved by the FDA. Previous data, released last November, showed the drug worked in patients with genotype 2 or 3 hepatitis C virus. Gilead now has data showing the drug works on genotypes 1 through 6.

Gilead Sciences, Inc. (NASDAQ:GILD)In the Neutrino trial, patients with genotype 1, 4, 5, or 6 hepatitis C infection were treated with sofosbuvir combined with ribavirin and Roche’s Pegasys for 12 weeks, which cured 90% of patients for the mixed population and 89% when you just look at genotype 1. Typically, ribavirin and Pegasys alone would produce a cure rate of about 60%. Adding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)‘  Incivek or Merck & Co., Inc. (NYSE:MRK)‘s  Victrelis to the regimen would increase the cure rate to as high as 79% for genotype 1 patients. It’s a little dangerous to compare Gilead’s data with Vertex’s and Merck’s data, since they might have enrolled patients with different underlying issues, but it appears sofosbuvir is at least as good, and perhaps better, than the first-generation offerings.

Gilead also presented additional data in patients with genotype 2 or 3. In the trial, dubbed Fission, sofosbuvir plus ribavirin only matched the cure rate of ribavirin and Pegasys, but that’s an acceptable result given Pegasys’ side effects. Adverse events observed in greater than 10% of patients — fatigue, headache, nausea, insomnia, and dizziness — all occurred in patients taking Pegasys.

Gilead has one more phase 3 trial, called Fusion, whose results are anticipated later this quarter, and then Gilead will be able to apply for FDA approval. Unless some safety issue crops up, an approval seems all but certain.

Just don’t thnk that sofosbuvir will produce massive sales all on its own. The largest opportunity in the U.S. is in genotype 1 patients, but sales of Incivek continue to fall as patients wait for an all-oral regimen. Remember Gilead only has data combining its drug with Pegasys in that genotype, so don’t expect patients to flock to it just yet.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!